Aytu BioPharma, Inc. Overview
Pro stress-test →Aytu BioPharma focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age. The company also maintains a pediatric portfolio addressing allergies and nutrient deficiencies.
Strategic Profile
Pro stress-test →Aytu Biopharma is a specialty pharmaceutical company focusing on developing and commercializing novel therapeutics and consumer healthcare products. The company is pursuing clinical development of AR101, a protein kinase inhibitor candidate for rare genetic disorders, positioning itself in niche therapeutic areas with significant unmet medical needs.
Competitive Landscape
Pro stress-test →Aytu competes in the crowded ADHD therapeutic market dominated by larger pharmaceutical players including Novartis (Ritalin), Shire/Takeda (Adhansia), and Johnson & Johnson (Concerta). In pediatric specialty products, competition includes established players like Pfizer and smaller specialty pharma firms. The company's differentiation rests on orally disintegrating tablet formulations and selective focus on pediatric populations.
Industry Context
Aytu BioPharma, Inc. operates in Specialty Pharmaceuticals.
Key facts
Founded: 2015 · Headquarters: Denver, Colorado